File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.2217/fon.11.95
- Scopus: eid_2-s2.0-80054113770
- PMID: 21992728
- WOS: WOS:000297101200009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Title | Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma |
---|---|
Authors | |
Keywords | combined targeting hepatocellular carcinoma PI3K/Akt/mTOR |
Issue Date | 2011 |
Citation | Future Oncology, 2011, v. 7 n. 10, p. 1149-1167 How to Cite? |
Abstract | Despite recent advances in the understanding of the biologic basis of hepatocellular carcinoma (HCC) development, the clinical management of the disease remains a major challenge. Deregulation of the PI3K/Akt/mTOR pathway, which is a prototypic survival pathway, is increasingly implicated in HCC carcinogenesis. In this article, we detailed the role of this pathway in the pathogenesis of HCC and provide an update on the preclinical and clinical development of various agents targeting this key survival/proliferation pathway, which include various PI3K inhibitors, Akt inhibitors and mTOR inhibitors for HCC. In addition, we highlighted the therapeutic potential of combination strategy for mTOR inhibitors with conventional chemotherapy, in particular, antimicrotubule agents, other molecular targeting agents, as well as radiotherapy. © 2011 Future Medicine Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/194330 |
ISSN | 2023 Impact Factor: 3.0 2023 SCImago Journal Rankings: 1.029 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhou, Q | - |
dc.contributor.author | Lui, VWY | - |
dc.contributor.author | Yeo, W | - |
dc.date.accessioned | 2014-01-30T03:32:27Z | - |
dc.date.available | 2014-01-30T03:32:27Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Future Oncology, 2011, v. 7 n. 10, p. 1149-1167 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | http://hdl.handle.net/10722/194330 | - |
dc.description.abstract | Despite recent advances in the understanding of the biologic basis of hepatocellular carcinoma (HCC) development, the clinical management of the disease remains a major challenge. Deregulation of the PI3K/Akt/mTOR pathway, which is a prototypic survival pathway, is increasingly implicated in HCC carcinogenesis. In this article, we detailed the role of this pathway in the pathogenesis of HCC and provide an update on the preclinical and clinical development of various agents targeting this key survival/proliferation pathway, which include various PI3K inhibitors, Akt inhibitors and mTOR inhibitors for HCC. In addition, we highlighted the therapeutic potential of combination strategy for mTOR inhibitors with conventional chemotherapy, in particular, antimicrotubule agents, other molecular targeting agents, as well as radiotherapy. © 2011 Future Medicine Ltd. | - |
dc.language | eng | - |
dc.relation.ispartof | Future Oncology | - |
dc.subject | combined targeting | - |
dc.subject | hepatocellular carcinoma | - |
dc.subject | PI3K/Akt/mTOR | - |
dc.title | Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.2217/fon.11.95 | - |
dc.identifier.pmid | 21992728 | - |
dc.identifier.scopus | eid_2-s2.0-80054113770 | - |
dc.identifier.volume | 7 | - |
dc.identifier.issue | 10 | - |
dc.identifier.spage | 1149 | - |
dc.identifier.epage | 1167 | - |
dc.identifier.isi | WOS:000297101200009 | - |
dc.identifier.issnl | 1479-6694 | - |